Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 142 clinical trials
featured
A PHASE 3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

="text-decoration: underline;">Primary: - To assess the change from baseline in estimated glomerular filtration rate (eGFR) at Week 52 following a 4-week drug

  • 63 views
  • 23 Nov, 2020
  • 2 locations
featured
Do You Have Osteoporosis?

Do You Have Osteoporosis?

  • 1122 views
  • 25 Mar, 2021
  • 1 location
Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

> Secondary Objective: To determine the effect of early versus delayed treatment with venglustat on the renal function (estimated glomerular filtration rate [eGFR]). To characterize

  • 0 views
  • 05 Mar, 2021
  • 1 location
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage and estimated glomerular filtration rate (eGFR) decline in

treatment regimen
glomerular filtration rate
urine osmolality
renal disease
chronic kidney disease
  • 82 views
  • 02 Apr, 2021
  • 130 locations
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

The purpose of this study is to evaluate the change in serum (blood) potassium levels from start of treatment to Day 14, when patiromer is administered at different doses, once daily, in children 2 - < 18 years of age with chronic kidney disease (CKD) and hyperkalemia (too much potassium …

  • 476 views
  • 15 Feb, 2021
  • 46 locations
Study of the Anti-FGF23 Antibody Burosumab in Adults With XLH

This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab (UX023-CL303 / UX023-CL304).

  • 32 views
  • 23 Jan, 2021
  • 11 locations
Twice Against Thrice-weekly Hemodialysis

Hemodialysis is the most worldwide prescribed renal replacement therapy for patients with end-stage renal disease. The frequency of sessions per week remains a debatable issue. In the majority of developed Western and Asian countries, patients on chronic hemodialysis are undergoing three dialysis sessions weekly. In developing countries and some developed …

hypertension
renal replacement therapy
chronic hemodialysis
chronic renal failure
  • 23 views
  • 26 Jan, 2021
  • 1 location
Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients

The objective of this study is to examine the effect on allograft function and histology of converting African American renal transplant recipients with chronic allograft nephropathy (CAN) from a tacrolimus-based regimen to a sirolimus-based maintenance immunosuppression regimen. The investigators hypothesize that the conversion from tacrolimus to sirolimus in African American …

  • 20 views
  • 08 Nov, 2020
  • 1 location
Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation

: incidence of tumors and cardiovascular events. The primary objective: To assess if superior graft function (glomerular filtration rate (GFR) difference of 10 ml/min) will be achieved at 1 year

calcineurin inhibitor
cyclosporine
myfortic
everolimus
  • 18 views
  • 07 Nov, 2020
  • 4 locations
Viral Load Guided Immunosuppression After Lung Transplantation

(TTV viral load in whole blood) compared to conventional calcineurin inhibitor dosing. Indicator for toxicity will be the glomerular filtration rate (GFR), which will be estimated using the CKD-EPI

  • 0 views
  • 26 Jan, 2021
  • 2 locations